Epigenetic alterations, including changes in DNA methylation, histone modifications and
nucleosome remodeling, result in abnormal gene expression patterns that contribute to …

Purpose: Aggressive variant prostate cancer (AVPC) represents a clinical subset
distinguished by therapy resistance and poor prognosis, linked to combined losses of the …

Background: In recent years, metastatic castration-resistant prostate cancer (MCRPC) and
studies related to MCRPC have drawn global attention. The main objective of this …

Context Multiple studies have reported on the genomic characteristics of metastatic hormone-
sensitive prostate cancer (mHSPC). The impact of these findings on prognostication …

Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate
cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its …

Background Abiraterone and enzalutamide are associated with side effects that may impair
health-related quality of life (HRQoL). Objective To assess patient-reported HRQoL …

Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA
released into the bloodstream primarily from cancer cells undergoing apoptosis. In …

Purpose: Prostate cancer is the second leading cause of male cancer deaths. Castration-
resistant prostate cancer (CRPC) is a lethal stage of the disease that emerges when …

In recent years, the introduction of new molecular techniques in experimental and clinical
settings has allowed researchers and clinicians to propose circulating-tumor DNA (ctDNA) …

Prostate cancer therapy for locally advanced and metastatic diseases includes androgen
deprivation therapy (ADT). Second-generation antiandrogens have a role in castration …